A universal monoclonal antibody-aptamer conjugation strategy for selective non-invasive bioparticle isolation from blood on a regenerative microfluidic platform. (15th October 2022)

• Record Type: Journal Article
• Authors: Chen, Yongli; Yang, Yikun; Feng, Jinglong; Carrier, Andrew J.; Tyagi, Deependra; Yu, Xin; Wang, Chunguang; Oakes, Ken D.; Zhang, Xu
• Is Part Of: Acta biomaterialia. Volume 152(2022)
• Page Start: 210
• Page End: 220
• Publication Date: 2022-10-15
• Subjects: Circulating tumor cell -- Microfluidics -- Aptamer -- Antibody -- Reusable diagnostic device -- Sustainable biomedical engineering; Biomedical materials -- Periodicals; 610.28
• DOI: 10.1016/j.actbio.2022.09.001
• Languages: English
• ISSNs: 1742-7061

Abstract

Abstract: Simultaneous isolation of various circulating tumor cell (CTC) subtypes from whole blood is useful in cancer diagnosis and prognosis. Microfluidic affinity separation devices are promising for CTC separation because of their high throughput capacity and automatability. However, current affinity agents, such as antibodies (mAbs) and aptamers (Apts) alone, are still suboptimal for efficient, consistent, and versatile cell analysis. By introducing a hybrid affinity agent, i.e., an aptamer-antibody (Apt-mAb) conjugate, we developed a universal and regenerative microchip with high efficiency and non-invasiveness in the separation and profiling of various CTCs from blood. The Apt-mAb conjugate consists of a monoclonal antibody that specifically binds the target cell receptor and a surface-bound aptamer that recognizes the conserved Fc region of the mAb. The aptamer then indirectly links the surface functionalization of the microfluidic channels to the mAbs. This hybrid affinity agent and the microchip platform may be widely useful for various bio-particle separations in different biological matrices. Further, the regeneration capability of the microchip improves data consistency between multiple uses and minimizes plastic waste while promoting environmental sustainability. Statement of significance: A hybrid affinity agent, Apt-mAb, consisting of a universal aptamer (Apt) that binds the conserved Fc region of monoclonal antibodies (mAbs) was developed. The invented nano-biomaterial combines the strengths and overcomes the weakness of both Apts and mAbs, thus changing the paradigm of affinity separation of cell subtypes. When Apt-mAb was used to fabricate microfluidic chips using a "universal screwdriver" approach, the microchip could be easily tuned to bind any cell type, exhibiting great universality. Besides high sensitivity and selectivity, the superior regenerative capacity of the microchips makes them reusable, which provides improved consistency and repeatability in cell profiling and opens a new approach towards in vitro diagnostic point-of-care testing devices with environmental sustainability and cost-effectiveness. Graphical abstract: Image, graphical abstract